Heather J. Landau

Hematology | Oncology
530 E 74th St
New York, NY 10021

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 179 publications

Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.

Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.

Journal: Blood cancer journal
Published: August 31, 2026

Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma.

Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma.

Journal: Science translational medicine
Published: July 29, 2026

Lesion-level PET/CT analysis to identify predictors of progression after BCMA CAR T-cell therapy in multiple myeloma.

Lesion-level PET/CT analysis to identify predictors of progression after BCMA CAR T-cell therapy in multiple myeloma.

Journal: Blood cancer journal
Published: June 18, 2026

Common Threshold of Measurable Disease Improperly Excludes Patients With AL Amyloidosis From Clinical Trials.

Common Threshold of Measurable Disease Improperly Excludes Patients With AL Amyloidosis From Clinical Trials.

Journal: American journal of hematology
Published: April 12, 2026

A Clinically Applicable Conversion Formula between NT-proBNP and BNP in Light-Chain Amyloidosis.

A Clinically Applicable Conversion Formula between NT-proBNP and BNP in Light-Chain Amyloidosis.

Journal: JACC. CardioOncology
Published: March 16, 2026

Systemic amyloid light-chain amyloidosis beyond ANDROMEDA: Diagnostic challenges and therapeutic updates.

Systemic amyloid light-chain amyloidosis beyond ANDROMEDA: Diagnostic challenges and therapeutic updates.

Journal: CA: a cancer journal for clinicians
Published: March 01, 2026

Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool.

Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 23, 2026

Clinical practice pattern of management of plasma cell dyscrasia for kidney transplant candidates and recipients in the United States.

Clinical practice pattern of management of plasma cell dyscrasia for kidney transplant candidates and recipients in the United States.

Journal: Journal of onco-nephrology
Published: February 18, 2026

A pilot trial evaluating lenalidomide and oral azacitidine with radiotherapy for patients with newly diagnosed and relapsed plasmacytoma.

A pilot trial evaluating lenalidomide and oral azacitidine with radiotherapy for patients with newly diagnosed and relapsed plasmacytoma.

Journal: Haematologica
Published: February 05, 2026

Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies.

Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies.

Journal: Clinical lymphoma, myeloma & leukemia
Published: January 30, 2026

Autologous stem cell transplantation for AL amyloidosis: a multicenter summary of outcomes 2010-2020.

Autologous stem cell transplantation for AL amyloidosis: a multicenter summary of outcomes 2010-2020.

Journal: Bone marrow transplantation
Published: December 18, 2025

Monoclonal gammopathy of renal significance from a hematologic perspective.

Monoclonal gammopathy of renal significance from a hematologic perspective.

Journal: Hematology. American Society of Hematology. Education Program
Published: December 05, 2025
Showing 1-12 of 179

Last Updated: 09/26/2026